Literature DB >> 15302213

Ebola and Marburg virus-like particles activate human myeloid dendritic cells.

Catharine M Bosio1, Brian D Moore, Kelly L Warfield, Gordon Ruthel, Mansour Mohamadzadeh, M Javad Aman, Sina Bavari.   

Abstract

The filoviruses, Ebola (EBOV) and Marburg (MARV), are potential global health threats, which cause deadly hemorrhagic fevers. Although both EBOV and MARV logarithmically replicate in dendritic cells (DCs), these viruses do not elicit DC cytokine secretion and fail to activate and mature infected DCs. Here, we employed virus-like particles (VLPs) of EBOV and MARV to investigate whether these genome-free particles maintain similar immune evasive properties as authentic filoviruses. Confocal microscopy indicated that human myeloid-derived DCs readily took up VLPs. However, unlike EBOV and MARV, VLPs induced maturation of DCs including upregulation of costimulatory molecules (CD40, CD80, CD86), major histocompatibility complex (MHC) class I and II surface antigens, and the late DC maturation marker CD83. The chemokine receptors CCR5 and CCR7 were also modulated on VLP-stimulated DCs, indicating that DC could migrate following VLP exposure. Furthermore, VLPs also elicited DC secretion of the pro-inflammatory cytokines TNF-alpha, IL-8, IL-6, and MIP-1alpha. Most significantly, in stark contrast to DC treated with intact EBOV or MARV, DC stimulated with EBOV or MARV VLPs showed enhanced ability to support human T-cell proliferation in an allogenic mixed lymphocyte response (MLR). Thus, our findings suggest that unlike EBOV and MARV, VLPs are effective stimulators of DCs and have potential in enhancing innate and adaptive immune responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302213     DOI: 10.1016/j.virol.2004.05.025

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  44 in total

1.  Identification of a small-molecule entry inhibitor for filoviruses.

Authors:  Arnab Basu; Bing Li; Debra M Mills; Rekha G Panchal; Steven C Cardinale; Michelle M Butler; Norton P Peet; Helena Majgier-Baranowska; John D Williams; Ishan Patel; Donald T Moir; Sina Bavari; Ranjit Ray; Michael R Farzan; Lijun Rong; Terry L Bowlin
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

Review 2.  Filovirus vaccines.

Authors:  Steven B Bradfute; John M Dye; Sina Bavari
Journal:  Hum Vaccin       Date:  2011-06-01

3.  Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells.

Authors:  Sheng Zhang; Rafael Cubas; Min Li; Changyi Chen; Qizhi Yao
Journal:  Mol Immunol       Date:  2009-04-18       Impact factor: 4.407

4.  Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells.

Authors:  Lawrence W Leung; Man-Seong Park; Osvaldo Martinez; Charalampos Valmas; Carolina B López; Christopher F Basler
Journal:  Immunol Cell Biol       Date:  2011-01-25       Impact factor: 5.126

Review 5.  Plant-derived virus-like particles as vaccines.

Authors:  Qiang Chen; Huafang Lai
Journal:  Hum Vaccin Immunother       Date:  2012-09-20       Impact factor: 3.452

6.  Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition.

Authors:  Osvaldo Martinez; Joshua Johnson; Balaji Manicassamy; Lijun Rong; Gene G Olinger; Lisa E Hensley; Christopher F Basler
Journal:  Cell Microbiol       Date:  2009-09-22       Impact factor: 3.715

7.  Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge.

Authors:  Zhiyuan Wen; Ling Ye; Yulong Gao; Lei Pan; Ke Dong; Zhigao Bu; Richard W Compans; Chinglai Yang
Journal:  Antiviral Res       Date:  2009-09-20       Impact factor: 5.970

8.  The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains.

Authors:  Ndongala M Lubaki; Philipp Ilinykh; Colette Pietzsch; Bersabeh Tigabu; Alexander N Freiberg; Richard A Koup; Alexander Bukreyev
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

9.  Discovery of common marburgvirus protective epitopes in a BALB/c mouse model.

Authors:  Warren V Kalina; Kelly L Warfield; Gene G Olinger; Sina Bavari
Journal:  Virol J       Date:  2009-08-27       Impact factor: 4.099

10.  A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Authors:  Robert B Mandell; Ramesh Koukuntla; Laura J K Mogler; Andrea K Carzoli; Alexander N Freiberg; Michael R Holbrook; Brian K Martin; William R Staplin; Nicholas N Vahanian; Charles J Link; Ramon Flick
Journal:  Virology       Date:  2009-11-24       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.